2009 Form 990-PF - Bill & Melinda Gates Foundation

BILL & MELINDA GATES FOUNDATION 56-2618866
FORM 990PF, PART XV - GRANTS AND CONTRIBUTIONS PAID DURING THE YEAR
RELATIONSHIP TO SUBSTANTIAL CONTRIBUTOR
AND
ATTACHMENT 18 (CONT'D)
RECIPIENT NAME AND ADDRESS FOUNDATION STATUS OF RECIPIENT PURPOSE OF GRANT OR CONTRIBUTION AMOUNT
INSTITUTE FOR COMPETITIVE WORKFORCE NONE TO DEEPLY ENGAGE THE BUSINESS COMMUNITY AROUND
1,328,374.
1615 H STREET NW 509(A)(1)
WASHINGTON, DC 20062
KEY COLLEGE READY GOALS, INCLUDING BETTER DATA
AND RIGOROUS COLLEGE READY ACADEMIC STANDARDS
INSTITUTE FOR ONE WORLD HEALTH NONE TO HELP AVERT VISCERAL LEISHMANIASIS-RELATED
4,734,617.
50 CALIFORNIA STREET 509(A)(1)
SUITE 500
SAN FRANCISCO, CA 94111
MORBIDITY AND MORTALITY IN SOUTH ASIA
INSTITUTE FOR ONE WORLD HEALTH NONE TO ESTABLISH AND VALIDATE A MANUFACTURING
1,667,303.
50 CALIFORNIA STREET 509(A)(1)
SUITE 500
SAN FRANCISCO, CA 94111
PROCESS TO MAKE ARTEMISININ-TYPE DRUGS
AFFORDABLE FOR THE WORLD'S POOREST PEOPLE
INSTITUTE FOR ONE WORLD HEALTH NONE TO SUPPORT THE REGIONAL ELIMINATION PROGRAM IN
4,936,161.
50 CALIFORNIA STREET 509(A)(1)
SUITE 500
SAN FRANCISCO, CA 94111
SOUTH ASIA BY GETTING A SAFE AND EFFECTIVE
TREATMENT FOR VISCERAL LEISHMANIASIS,
PAROMOMYCIN INTRAMUSCULAR INJECTION,
REGISTERED AND ADOPTED BY THE GOVERNMENTS OF
BANGLADESH AND NEPAL
INSTITUTE FOR ONE WORLD HEALTH NONE FOR INDUSTRIALIZATION/SCALE-UP OF BIOSYNTHETIC
438,565.
50 CALIFORNIA STREET 509(A)(1)
SUITE 500
SAN FRANCISCO, CA 94111
MALARIA DRUG WITH SANOFI: TRANSITION
SUCCESSFUL GENETIC PLATFORM ORGANISM TO
COMMERCIAL FERMENTATION SCALE-UP WITH SANOFI
AVENTIS FOR BIOSYNTHETIC ARTEMISININ
INSTITUTE FOR ONE WORLD HEALTH NONE TO DESIGN AND DEVELOP A PHASE 3 CLINICAL TRIAL
2,178,854.
50 CALIFORNIA STREET 509(A)(1)
SUITE 500
SAN FRANCISCO, CA 94111
FOR PUBLIC DISCLOSURE
115 OF 519
TRAINING AND MENTORSHIP PROGRAM IN INDIA
ATTACHMENT 18